Celltrion USA has officially announced the U.S. launch of its denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo), marking a significant development in the biosimilar therapeutics market. These new additions offer more accessible treatment options for patients requiring denosumab, a monoclonal antibody commonly prescribed for osteoporosis and certain cancer-related bone conditions. The introduction of STOBOCLO® and OSENVELT® underscores Celltrion’s commitment to expanding affordable biopharmaceutical alternatives in the United States, promising to enhance patient access while potentially reducing healthcare costs.
Celltrion USA Expands Osteoporosis Treatment Options with Launch of Denosumab Biosimilars
Celltrion USA has officially launched two denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo), marking a significant milestone in expanding accessible treatment options for patients with osteoporosis. These biosimilars offer equivalent efficacy and…
—-
Author : Sophia Davis
Publish date : 2025-07-08 09:03:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
